scispace - formally typeset
J

Jonathan G. Seidman

Researcher at Harvard University

Publications -  597
Citations -  104873

Jonathan G. Seidman is an academic researcher from Harvard University. The author has contributed to research in topics: Gene & Hypertrophic cardiomyopathy. The author has an hindex of 137, co-authored 563 publications receiving 89782 citations. Previous affiliations of Jonathan G. Seidman include Albert Einstein College of Medicine & Rutgers University.

Papers
More filters
Journal ArticleDOI

Comprehensive molecular characterization of human colon and rectal cancer

Donna M. Muzny, +320 more
- 19 Jul 2012 - 
TL;DR: Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.
Journal ArticleDOI

The cancer genome atlas pan-cancer analysis project

John N. Weinstein, +379 more
- 01 Oct 2013 - 
TL;DR: The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA with a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages.
Journal Article

The Cancer Genome Atlas Pan-Cancer analysis project

Kyle Chang, +337 more
- 01 Sep 2013 - 
TL;DR: The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels as mentioned in this paper.
Journal ArticleDOI

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass, +257 more
- 11 Sep 2014 - 
TL;DR: A comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project is described and a molecular classification dividing gastric cancer into four subtypes is proposed.
Journal ArticleDOI

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Michael S. Lawrence, +309 more
- 29 Jan 2015 - 
TL;DR: It is shown that human-papillomavirus-associated tumours are dominated by helical domain mutations of the oncogene PIK3CA, novel alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1.